

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

102120

5730

Licensee

In accordance with letter dated

June 7, 2010,

3. License number 13-12367-01 is amended in its entirety as follows:

4. Expiration date **October 31, 2014**

5. Docket No. **030-01658**
Reference No.

- 1. Clark Memorial Hospital
- 2. 1220 Missouri Avenue
Jeffersonville, IN 47130

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

- A. Any byproduct material permitted by 10 CFR 35.100
- B. Any byproduct material permitted by 10 CFR 35.200
- C. Any byproduct material permitted by 10 CFR 35.300
- D. Any byproduct material permitted by 10 CFR 35.400
- E. Any byproduct material permitted by 10 CFR 31.11
- F. Strontium-90

- A. Any
- B. Any
- C. Any
- D. Sealed sources (Bard Brachytherapy Model No. STM-1251 and Theragenics Model No. 200)
- E. Prepackaged kits
- F. Sealed source (Tracerlab Model RA-2A)

- A. As needed
- B. As needed
- C. Not to exceed 1 curie
- D. Not to exceed 2 curies
- E. As needed
- F. One source not to exceed 100 millicuries

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging or localization study permitted by 10 CFR 35.200.
- C. Any therapy procedure permitted by 10 CFR 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-12367-01

Docket or Reference Number

030-01658

Amendment No. 34

- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. In vitro studies.
- F. For possession only, incident to disposal.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 1220 Missouri Avenue, Jeffersonville, Indiana.
11. Radiation Safety Officer: Kevin P. Serey, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical uses:

Authorized Users

Material and Use

| | |
|---------------------------|---|
| H. David Heideman, M.D. | 10 CFR 35.100, 35.200, 35.300 and 31.11. |
| David R. Cannon, M.D. | 10 CFR 35.100, 35.200 and 31.11. |
| Mohammed Hussain, M.D. | 10 CFR 35.100 and 35.200. |
| Dolph Martel Denny, M.D. | 10 CFR 35.100 and 35.200. |
| William R. Fortner, M.D. | 10 CFR 35.100, 35.200, 35.300 and 31.11. |
| Stephen R. Regan, M.D. | 10 CFR 35.100, 35.200, 35.300 and 31.11. |
| Edsel S. Reed, M.D. | 10 CFR 35.100, 35.200, 35.300 and 31.11. |
| Anthony Duncan, M.D. | 10 CFR 35.100, 35.200, 35.300 and 31.11 |
| Kelly J. Colomb, M.D. | 10 CFR 35.100, 35.200, 35.300 and 31.11 |
| Bapineedu Gondi, M.D. | 10 CFR 35.100 and 35.200. |
| Gary Yurow, M.D. | 10 CFR 35.100 and 35.200. |
| Stephen J. Matthews, M.D. | 10 CFR 35.100, 35.200 and 35.300 excluding thyroid carcinoma therapy. |
| Michael M. Tate, M.D. | 10 CFR 35.100, 35.200, 35.300 and 31.11. |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-12367-01Docket or Reference Number
030-01658

Amendment No. 34

| | |
|-----------------------------------|---|
| Koduvathara James, M.D. | 10 CFR 35.100 and 35.200. |
| Carl E. Dillman, M.D. | 10 CFR 35.100 and 35.200. |
| D. Mark Bickers, M.D. | 10 CFR 35.100 and 35.200. |
| Wayne Shugoll, M.D. | 10 CFR 35.100 and 35.200. |
| Armand Rothschild, M.D. | 10 CFR 35.100 and 35.200. |
| Gurbachan Sohi, M.D. | 10 CFR 35.100 and 35.200. |
| Sohail Ikram, M.D. | 10 CFR 35.100 and 35.200. |
| Thomas Matthew Sweat, M.D. | 10 CFR 35.100 and 35.200. |
| William J. Schoen, M.D. | 10 CFR 35.100 and 35.200. |
| John Terrence Kenny, M.D. | 10 CFR 35.100 and 35.200. |
| Frederick Albrink, M.D. | 10 CFR 35.300 and 35.400. |
| Zaka Ur Rahman, M.D. | 10 CFR 35.100 and 35.200. |
| Craig S. Kamen, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| F. Baby Jose, M.D. | 10 CFR 35.400. |
| Mark Cornett, M.D. | 10 CFR 35.400. |
| Mark Jones, M.D. | 10 CFR 35.400 |
| Zulfiqar Bhatti, M.D. | 10 CFR 35.100 and 35.200. |
| Brian Worm, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| Ali Nawab Risvi, M.D. | 10 CFR 35.100 and 35.200. |
| Geoffrey Peters, M.D. | 10 CFR 35.100 and 35.200. |
| Srinivasarao Manchikalapudi, M.D. | 10 CFR 35.100 and 35.200. |
| Kendall Goldschmidt, M.D. | 10 CFR 35.100 and 35.200 and 35.300. |
| Christopher J. Day, M.D. | 10 CFR 35.100 and 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma). |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-12367-01

Docket or Reference Number
030-01658

Amendment No. 34

| | |
|---------------------------|--|
| Kevin E. Burton, M.D. | 10 CFR 35.100 and 35.200. |
| Thomas C. Passo, M.D. | 10 CFR 35.100 and 35.200. |
| Naresh Solankhi, M.D. | 10 CFR 35.100 and 35.200. |
| Naveen Devabhaktuni, M.D. | 10 CFR 35.100 and 35.200. |
| Mitchell Jay Kline, M.D. | 10 CFR 35.100 and 35.200. |
| Jerome Schrodt, M.D. | 10 CFR 35.100, 35.200 and oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries. |
| Richard Eickler, M.D. | 10 CFR 35.100 and 35.200. |
| Kevin P. Serey, M.D. | 10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131. |
| David P. Musich, M.D. | 10 CFR 35.300, 35.400 and 31.11. |
| Larry M. Leslie, M.D. | 10 CFR 35.100 and 35.200. |
| Paul J. Rogers, M.D. | 10 CFR 35.100 and 35.200. |
| Andrea Walker, D.O. | 10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131. |
| Barbara Pawley, M.D. | 10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries. |
| Emily Folz, M.D. | 10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131 |

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-12367-01Docket or Reference Number
030-01658


Amendment No. 34

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 22, 2004; and,
 - B. Letter received October 21, 2004; and
 - C. Letter dated October 17, 2008 and **June 7, 2010**.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 15 2010

By

Toye L. Simmons
Materials Licensing Branch
Region III